Abstract
Background: The introduction of cisplatin-based chemotherapy has remarkably increased the survival of testicular cancer patients. With this success, the concern for a contraIateral testicular tumor has increased. The aim of this study was to investigate whether the risk for contralateral testicular tumor development was influenced by cisplatin-based chemotherapy,
Methods: The incidence of a contralateraI testicular tumor among 365 consecutive patients with a nonseminoma testicular tumor, diagnosed in the period 1980 and 1995, was established and related to previous therapy.
Results: Eleven of 365 men (3%) developed a contralateral testicular tumor, After a total of 2403 person-pears at risk, 4 of 225 chemotherapy-treated patients (1.8%) developed a contralateraI testicular tumor, and 7 of 140 patients (5%) treated with orchidectomy alone developed a contralateraI tumor. In comparison to this surveillance subgroup, patients previously treated with chemotherapy have a relative risk of 0.30 to develop a second testicular tumor.
Conclusions: In Dutch men with a nonseminoma testicular tumor, the incidence of a contralateral testicular tumor is 3%, which is 60-fold the expected incidence rate of testicular cancer, A three times lower incidence rate of a contralateral testicular tumor was found in the chemotherapy subgroup compared with those on surveillance. This supports the hypothesis that cisplatin-based chemotherapy may eradicate carcinoma in situ or early testicular cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 342-348 |
| Number of pages | 7 |
| Journal | Annals of Surgical Oncology |
| Volume | 4 |
| Issue number | 4 |
| Publication status | Published - Jun-1997 |
| Event | 49th Annual Cancer Symposium of the Society-of-Surgical-Oncology - , Gabon Duration: 21-Mar-1996 → 25-Mar-1996 |
Keywords
- bilateral testicular cancer
- cisplatin
- incidence
- GERM-CELL TUMORS
- CARCINOMA-INSITU
- CONTRALATERAL TESTIS
- FOLLOW-UP
- RISK
- SEMINOMA
- EXPERIENCE